Breast Cancer Clinical Trial
— PW2Official title:
Pink Warrior 2.0: Teleconference Support Group Toolkit for Breast Cancer Survivors
Verified date | May 2023 |
Source | The University of Texas Medical Branch, Galveston |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Breast cancer survivors, from diagnosis until the end of life, go through many transitions. One major transition is the significant decrease of physical activity immediately after diagnosis. Despite the known benefits of physical activity-speeding recovery time and reduced cancer recurrence risk-only 1 in 3 survivors met physical activity recommendations of 150 minutes of moderate-intensity activity per week. Physical activity interventions have shown effectiveness in helping breast cancer survivors increase physical activity during treatment, but limited evidence-based physical activity interventions have been incorporated into the clinic and community. To address this limitation, the investigators are partnering with the UTMB breast cancer support group to conduct a 12-week physical activity intervention, Pink Warrior. The goal of this study is to compare an intervention that uses active games versus an intervention uses pedometer to encourage physical activity such as walking within breast cancer survivors in active cancer treatment. The study will include breast cancer survivor between the ages of 18 - 70 whom currently gets less than 150 minutes of planned physical activity per week and received a breast cancer diagnosis within 0 to 6 months. Participants will be randomized to participate in the support group using the active video game-based physical activity intervention (Wii and Xbox active games) or to participate in the existing UTMB breast cancer support group with pedometers (Digi-Walker CW-700/701). The investigators hypothesize that by engaging in active video gaming, breast cancer survivors will be motivated to initiate and maintain physical activity during treatment. This will ultimately increase functional capacity and prevent functional disability in breast cancer survivors.
Status | Completed |
Enrollment | 20 |
Est. completion date | March 29, 2022 |
Est. primary completion date | January 29, 2022 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 55 Years to 79 Years |
Eligibility | Inclusion Criteria: 1. Provide informed consent 2. Diagnosed with primary female breast cancer 3. 55 years to 79 4. Able to speak, read, and write in English 5. Able to travel to UTMB locations and/or MD Anderson Victory Lakes 6. Able to move arms and les as well as ambulate 7. Has a smartphone, tablet or computer and daily access to a reliable internet Exclusion Criteria: 1. Pregnancy 2. Diagnosed dementia 3. Currently engage in 150 minutes or more of planned moderate intensity physical activity 4. Currently involved in another physical activity intervention |
Country | Name | City | State |
---|---|---|---|
United States | The University of Texas Medical Branch | Galveston | Texas |
United States | UT MD Anderson Cancer Center | Houston | Texas |
Lead Sponsor | Collaborator |
---|---|
The University of Texas Medical Branch, Galveston | M.D. Anderson Cancer Center, National Institute on Aging (NIA) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Walking Skills in Daily Life | Walking skills as measured by the Figure-of-8 Walk test | Baseline to 14 weeks | |
Other | Hand Grip Strength | Flexor muscle strength of hand and forearm measured by dynamometer | Baseline to 14 weeks | |
Other | Physical Function as Measured by the Senior Fitness Test | Physical function scores on six components: chair stands, arm curls, chair sit and reach, back scratch, 8 foot up and go, and 2 minute step in place test | Baseline to 14 weeks | |
Other | Body Weight in kg | Mean body weight as measured by a calibrated scale in a cancer clinic setting | Baseline to 14 weeks | |
Other | Waist Circumference in cm | Mean waist circumference as measured by Seca-203 measuring tape | Baseline to 14 weeks | |
Other | Dietary Pattern | Dietary pattern change measured by the National Health and Nutrition Examination Survey (2009-10) measuring fruits, vegetables, dairy/calcium, added sugar, whole grains/fiber, red meat, and processed meat consumption within the past 30 days | Baseline to 14 weeks | |
Other | Self-reported Physical Activity Minutes | Minutes of physical activity as self-reported using the Community Healthy Activities Model Program for Seniors questionnaire | Baseline to 14 weeks | |
Other | Self-reported Physical Function | Physical function score as measured by the PROMIS cancer-specific instrument (PROMIS-CA Bank v1.1-Physical Function) | Baseline to 14 weeks | |
Other | Fatigue | Fatigue score as measured by the PROMIS cancer-specific instrument (PROMIS-Ca Bank v1.1-Fatigue) | Baseline to 14 weeks | |
Other | Exercise Motivation Measured as Autonomous Regulation | Autonomous regulation as measured by the Behavioral Regulation in Exercise Questionnaire-2 | Baseline to 14 weeks | |
Other | Psychological Feelings Related to Exercise | Perceptions of autonomy, competence, and relatedness as measured by the Basic Psychological Needs in Exercise scale. 11 items on a 5-point Likert scale. Range: 1 (I do not agree at all) to 5 (I completely agree) for each of the constructs-autonomy (1-20), competence (1-20), and relatedness (1-15). The higher the score means more autonomy, more competence, and relatedness. | Baseline to 14 weeks | |
Other | Self-regulation: Exercise Goal-Setting (EGS) and Exercise Planning and Scheduling Scale (EPS) | Goal-setting and planning measures, adapted from a published, untitled series of items created by Rovniak et al for evaluation of technology-mediated health promotion content. 10 EGS and 10 EPS items on a 5-point Likert scale. Range: 1 (does not describe) to 5 (describes completely) of the goal setting and planning strategies. The higher the score means more exercise goal-setting and planning behavior. (Rovniak et al. Annals of Behavioral Medicine, 2002, 24(2): 149-156.) | Baseline to 14 weeks | |
Other | Feasibility - Adherence | Adherence as measured by number of participants who complete at least 80% of program activities | Baseline to 14 weeks | |
Other | Feasibility - Attrition | Attrition as measured by percentage of people who drop out of the program | Baseline to 14 weeks | |
Other | Feasibility - Technological Issues | Technological issues will be measured by counting the number of reported occurrences | Baseline to 14 weeks | |
Other | Feasibility - Adverse Events | Adverse events will be measured by counting the number of occurrences | Baseline to 14 weeks | |
Other | Acceptability Scale | Acceptability and satisfaction will be assessed via Vandelanotte questionnaire with 5-point scale responses, measures are adapted from a published, untitled series of items created by Vandelanotte et al for evaluation of technology-mediated health promotion content. Acceptability and feasibility of 3 components on a 5-point Likert scale-activity monitor (7-item), program team (6-item), and the program itself (15-item). Ranged: 1 (strongly disagree) to 5 (strongly agree). The higher the score means that it is more acceptable and feasible.
(Vandelanotte, C. and I. De Bourdeaudhuij (2003). "Acceptability and feasibility of a computer-tailored physical activity intervention using stages of change: project FAITH." Health Educ Res 18(3): 304-317 and Vandelanotte, C., et al. (2004). "Acceptability and feasibility of an interactive computer-tailored fat intake intervention in Belgium." Health Promot Int 19(4): 463-470.) |
Baseline to 14 weeks | |
Primary | Walking Physical Activity as Measured by Change in Daily Steps From Baseline to 14 Weeks | Difference in mean of daily steps taken from Actigraph accelerometer worn for 7 day period from baseline assessment to 14 week assessment | Baseline to 14 weeks | |
Secondary | Quality of Life as Measured by the Change in FACT-B Scores From Baseline to 14 Weeks | Quality of life score as measured by the Functional Assessment of Cancer Therapy-Breast measure at follow-up, scored for physical, social, emotional, functional, and breast well-being (here we report the total score of these subscales). The range for this scale is 0-123, with 0 indicating a better outcome. | Baseline to 14 weeks | |
Secondary | Physical Performance as Measured by the Change in Short Physical Performance Battery Scores From Baseline to 14 Weeks | Difference in physical performance as measured by Short Physical Performance Battery from baseline to 14 weeks. The numbers reported here are the sum of scores from the subscales. The range for this measure is between 0-12, with lower scores indicating better outcomes. | Baseline to 14 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |